Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,790 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of gefitinib on warfarin antithrombotic activity.
Arai S, Mitsufuji H, Nishii Y, Onoda S, Ryuge S, Wada M, Katono K, Iwasaki M, Takakura A, Otani S, Yamamoto M, Yanaihara T, Yokoba M, Kubota M, Katagiri M, Fukui T, Kobayashi H, Yanase N, Hataishi R, Masuda N. Arai S, et al. Among authors: wada m. Int J Clin Oncol. 2009 Aug;14(4):332-6. doi: 10.1007/s10147-008-0871-2. Epub 2009 Aug 25. Int J Clin Oncol. 2009. PMID: 19705244
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Otani S, Hamada A, Sasaki J, Wada M, Yamamoto M, Ryuge S, Takakura A, Fukui T, Yokoba M, Mitsufuji H, Toyooka I, Maki S, Kimura M, Hayashi N, Ishihara M, Kasajima M, Hiyoshi Y, Katono K, Asakuma M, Igawa S, Kubota M, Katagiri M, Saito H, Masuda N. Otani S, et al. Among authors: wada m. Am J Clin Oncol. 2015 Aug;38(4):405-10. doi: 10.1097/COC.0b013e3182a2d98d. Am J Clin Oncol. 2015. PMID: 26214085 Clinical Trial.
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
Wada M, Yamamoto M, Ryuge S, Nagashima Y, Hayashi N, Maki S, Otani S, Katono K, Takakura A, Yanaihara T, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Masuda N. Wada M, et al. Cancer Chemother Pharmacol. 2012 Apr;69(4):1005-11. doi: 10.1007/s00280-011-1795-5. Epub 2011 Dec 8. Cancer Chemother Pharmacol. 2012. PMID: 22160350 Clinical Trial.
Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
Yanaihara T, Yokoba M, Onoda S, Yamamoto M, Ryuge S, Hagiri S, Katagiri M, Wada M, Mitsufuji H, Kubota M, Arai S, Kobayashi H, Yanase N, Abe T, Masuda N. Yanaihara T, et al. Among authors: wada m. Cancer Chemother Pharmacol. 2007 Mar;59(4):419-27. doi: 10.1007/s00280-006-0279-5. Epub 2006 Jul 11. Cancer Chemother Pharmacol. 2007. PMID: 16832665 Clinical Trial.
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Asakuma M, Yamamoto M, Wada M, Ryuge S, Katono K, Yokoba M, Fukui T, Takakura A, Otani S, Maki S, Igawa S, Yanaihara T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Masuda N. Asakuma M, et al. Among authors: wada m. Cancer Chemother Pharmacol. 2012 Jun;69(6):1529-36. doi: 10.1007/s00280-012-1858-2. Epub 2012 Mar 14. Cancer Chemother Pharmacol. 2012. PMID: 22415148 Clinical Trial.
Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI).
Harada H, Seto T, Igawa S, Tsuya A, Wada M, Kaira K, Naito T, Hayakawa K, Nishimura T, Masuda N, Yamamoto N. Harada H, et al. Among authors: wada m. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1777-82. doi: 10.1016/j.ijrobp.2011.03.037. Epub 2011 May 27. Int J Radiat Oncol Biol Phys. 2012. PMID: 21621337 Clinical Trial.
2,790 results